石藥集團(01093.HK)：安尼妥單抗(KN026)與注射用多西他賽(白蛋白結合型)(HB1801)新輔助治療的新藥上市申請獲國家藥監局受理

智通財經

08/04

【石藥集團(01093.HK)：安尼妥單抗(KN026)與注射用多西他賽(白蛋白結合型)(HB1801)新輔助治療的新藥上市申請獲國家藥監局受理】智通財經APP訊，石藥集團(01093.HK)發布公告，本公司附屬公司上海津曼特生物科技有限公司與江蘇康寧傑瑞生物製藥有限公司合作開發的安尼妥單抗(KN026)聯合本集團自主研發的注射用多西他賽(白蛋白結合型)(HB1801)新輔助治療的新藥上市申請已獲中華人民共和國國家藥品監督管理局(國家藥監局)受理，並納入優先審評審批程序。本次申請適應症為安尼妥單抗聯合多西他賽(白蛋白結合型)±卡鉑新輔助治療早期或局部晚期HER2陽性成人乳腺癌。

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎證券香港 | 輕鬆買賣美股港股A股/美債/ETF/Crypto/期權期貨","description":"老虎證券香港提供多種優惠: 港股&Crypto 0佣、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投，即時串流報價與多種工具，立即開戶享更多優惠！","keywords":"老虎證券,老虎證券開戶,老虎證券香港,老虎證券投資,老虎證券美股,老虎證券登錄,證券開戶,證券公司開戶,股票開戶,香港證券公司,香港證券,證券公司,美股投資平台,小額投資理財,投資app,投資平台,股票買賣,買賣股票平台,炒股app,證券app,新手投資","social":{"ogDescription":"老虎證券香港提供多種優惠: 港股&Crypto 0佣、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投，即時串流報價與多種工具，立即開戶享更多優惠！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.atigrdive.com/hant/news/2656534115"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2656534115\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2656534115?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":false,"pubTime":"2026-08-04 18:04","share_image_url":"https://static.laohu8.com/6ca2dcdccfa2217fb20a0351f4efe814","id":"2656534115","market":"hk","top_or_hot":-1,"title":"石藥集團(01093.HK)：安尼妥單抗(KN026)與注射用多西他賽(白蛋白結合型)(HB1801)新輔助治療的新藥上市申請獲國家藥監局受理","media":"智通財經","content":"<html><body><div>\n<div>\n<b>【石藥集團(01093.HK)：安尼妥單抗(KN026)與注射用多西他賽(白蛋白結合型)(HB1801)新輔助治療的新藥上市申請獲國家藥監局受理】</b>智通財經APP訊，石藥集團(01093.HK)發布公告，本公司附屬公司上海津曼特生物科技有限公司與江蘇康寧傑瑞生物製藥有限公司合作開發的安尼妥單抗(KN026)聯合本集團自主研發的注射用多西他賽(白蛋白結合型)(HB1801)新輔助治療的新藥上市申請已獲中華人民共和國國家藥品監督管理局(國家藥監局)受理，並納入優先審評審批程序。本次申請適應症為安尼妥單抗聯合多西他賽(白蛋白結合型)±卡鉑新輔助治療早期或局部晚期HER2陽性成人乳腺癌。                </div>\n</div></body></html>","source":"live_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>石藥集團(01093.HK)：安尼妥單抗(KN026)與注射用多西他賽(白蛋白結合型)(HB1801)新輔助治療的新藥上市申請獲國家藥監局受理</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n石藥集團(01093.HK)：安尼妥單抗(KN026)與注射用多西他賽(白蛋白結合型)(HB1801)新輔助治療的新藥上市申請獲國家藥監局受理\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">智通財經</strong><span class=\"h-time small\">2026-08-04 18:04</span>\n</p>\n</h4>\n</header>\n<article>\n<html><body><div>\n<div>\n<b>【石藥集團(01093.HK)：安尼妥單抗(KN026)與注射用多西他賽(白蛋白結合型)(HB1801)新輔助治療的新藥上市申請獲國家藥監局受理】</b>智通財經APP訊，石藥集團(01093.HK)發布公告，本公司附屬公司上海津曼特生物科技有限公司與江蘇康寧傑瑞生物製藥有限公司合作開發的安尼妥單抗(KN026)聯合本集團自主研發的注射用多西他賽(白蛋白結合型)(HB1801)新輔助治療的新藥上市申請已獲中華人民共和國國家藥品監督管理局(國家藥監局)受理，並納入優先審評審批程序。本次申請適應症為安尼妥單抗聯合多西他賽(白蛋白結合型)±卡鉑新輔助治療早期或局部晚期HER2陽性成人乳腺癌。                </div>\n</div></body></html>\n<div class=\"bt-text\">\n\n\n<p> 來源：<a href=\"https://www.zhitongcaijing.com/immediately.html?type=ganggu\">智通財經</a></p>\n<p>為提升您的閱讀體驗，我們對本頁面進行了排版優化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01093","symbol_name":"石藥集團","start_time":0,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","article_id":"2656534115","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2656534115","pubTimestamp":1785837894,"columns":[],"sourceInfo":{"source_id":"live_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"【石藥集團(01093.HK)：安尼妥單抗(KN026)與注射用多西他賽(白蛋白結合型)(HB1801)新輔助治療的新藥上市申請獲國家藥監局受理】智通財經APP訊，石藥集團(01093.HK)發布公告","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"01093":"石药集团","LU0315179316.USD":"EASTSPRING INVESTMENTS ASIAN DYNAMIC \"A\" (USD) ACC","LU0067412154.USD":"UBS (LUX) EQUITY FUND -  CHINA OPPORTUNITY \"P\" (USD) ACC","KURE":"KraneShares MSCI All China Health Care Index ETF","BK1191":"制药","IE00BZ08YS42.EUR":"GUINNESS BEST OF CHINA \"C\" (EUR) ACC","LU0140636845.USD":"施罗德大中华区股票A Acc","LU1328277881.USD":"MANULIFE GF DRAGON GROWTH FUND \"AA\" (USD) INC","IE00BZ08YT58.USD":"GUINNESS BEST OF CHINA \"C\" (USD) ACC","LU1152091754.HKD":"UBS (LUX) EQUITY FUND - CHINA OPPORTUNITY (USD) \"PM\" (HKD) INC","SG9999004220.SGD":"Nikko AM Shenton Asia Dividend Equity Fund  SGD","IE0008369823.USD":"FSSA HONG KONG GROWTH \"I\" ACC","LU0314109678.HKD":"MANULIFE GF DRAGON GROWTH \"AA\" (HKD) INC","BK1515":"抗疫概念","LU1226288253.USD":"UBS (LUX) KEY SELECTION SICAV - CHINA ALLOCATION  OPPORTUNITY (USD) \"P\" (USD) INC","LU0072913022.USD":"UBS (LUX) EQUITY FUND -  GREATER CHINA \"P\" (USD) ACC","IE00B031HY20.USD":"FSSA CHINA GROWTH \"I\" (USD) INC","IE00B543WZ88.USD":"NEUBERGER BERMAN CHINA EQUITY \"A\" (USD) ACC","LU1226288170.HKD":"UBS (LUX) KEY SEL S-CHINA ALLOCATION OPP \"P6%\"(HK D) INC","LU1226287529.USD":"UBS (LUX) KEY SELECTION SICAV - CHINA ALLOCATION  OPPORTUNITY (USD) \"P\" (USD) ACC","LU1226287875.USD":"UBS (LUX) KEY SEL S-CHINA ALLOCATION OPP \"PM\" (USD) INC","LU0880133367.SGD":"UBS (LUX) EQUITY FUND CHINA OPPORTUNITY USD \"P\" (SGD) ACC","BK1521":"挪威政府全球养老基金持仓","LU1008478684.HKD":"UBS (LUX) EQUITY FUND -  CHINA OPPORTUNITY \"P\" (HKD) ACC","HK0000165453.HKD":"华夏精选大中华科技基金 A类港币","LU0326950275.SGD":"Schroder ISF China Opportunities A Acc SGD-H","IE00BZ08YR35.GBP":"GUINNESS BEST OF CHINA \"C\" (GBP) ACC","LU2039709279.SGD":"MANULIFE GF DRAGON GROWTH \"AA\" (SGDHDG) INC","LU1951186391.HKD":"UBS (LUX) KEY SEL CHINA ALLOCATION OPPORTUNITY (US \"P\" (HKD) INC","IE0008368742.USD":"首域中国增长基金I Acc","IE00B5MMRT66.SGD":"NEUBERGER BERMAN CHINA EQUITY \"A\" (SGDHDG) ACC","LU1813983027.USD":"MANULIFE GF DRAGON GROWTH \"AA\" (USD) INC","LU1152091168.USD":"UBS (LUX) EQUITY FUND - CHINA OPPORTUNITY (USD) \"PM\" INC","LU1807302812.USD":"UBS (LUX) EQUITY SICAV ALL CHINA \"P\" (USD) ACC","LU1993786604.SGD":"UBS (LUX) EQUITY SICAV ALL CHINA \"P\" (SGD) ACC","LU1960683339.HKD":"UBS (LUX) EQUITY SICAV ALL CHINA \"P\" (HKD) ACC","LU1226287792.SGD":"UBS (LUX) KEY SEL S-CHINA ALLOCATION OPP \"P\" (SGDHDG) INC","LU0501845795.SGD":"瑞银大中华区股票基金P Acc SGD"},"translate_title":"CSPC (01093.HK): New drug marketing application for neoadjuvant therapy of anituzumab (KN026) and docetaxel for injection (albumin-bound) (HB1801) was accepted by the NMPA","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01093":1.5,"KURE":0.6},"content_text":"【石藥集團(01093.HK)：安尼妥單抗(KN026)與注射用多西他賽(白蛋白結合型)(HB1801)新輔助治療的新藥上市申請獲國家藥監局受理】智通財經APP訊，石藥集團(01093.HK)發布公告，本公司附屬公司上海津曼特生物科技有限公司與江蘇康寧傑瑞生物製藥有限公司合作開發的安尼妥單抗(KN026)聯合本集團自主研發的注射用多西他賽(白蛋白結合型)(HB1801)新輔助治療的新藥上市申請已獲中華人民共和國國家藥品監督管理局(國家藥監局)受理，並納入優先審評審批程序。本次申請適應症為安尼妥單抗聯合多西他賽(白蛋白結合型)±卡鉑新輔助治療早期或局部晚期HER2陽性成人乳腺癌。","kind":"live","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":true,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}